SCHEMBL3029084

SCHEMBL3029084

CCOP(=O)(CNC(=O)CCCN)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
ENTPD2 Q9Y5L3 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
GAA P10253 1/20 0.38
SLC6A5 Q9Y345 2/20 0.37
TSHR P16473 2/20 0.36
PPARD Q03181 1/20 0.36
FAAH O00519 2/20 0.34
RECQL P46063 1/20 0.34
ENPP2 Q13822 1/20 0.34
LPAR1 Q92633 1/20 0.34
LPAR2 Q9HBW0 1/20 0.34
PLAU P00749 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
FPR2 P25090 1/20 0.33
TPSAB1 Q15661 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3029081 0.98 CYP1A2 (0.41) CYP1A2ENTPD2CA1CA2CA12
SCHEMBL3008229 0.90 TSHR (0.39) CYP1A2ENTPD2CA1CA2CA12
Hydrochloric Acid SCHEMBL3008227 0.88 TSHR (0.38) CYP1A2ENTPD2CA1CA2CA12
SCHEMBL3018969 0.82 TSHR (0.41) ENTPD2CA1CA2CA12CA9
SCHEMBL15127565 0.82 TSHR (0.41) ENTPD2CA1CA2CA12CA9
SCHEMBL5273397 0.81 TSHR (0.38) ENTPD2CA1CA2CA12CA9
SCHEMBL3102797 0.80 ENTPD2 (0.42) ENTPD2CA1CA2CA12CA9
SCHEMBL14948790 0.78 TSHR (0.44) ENTPD2CA1CA2CA12CA9
SCHEMBL5275146 0.77 TSHR (0.40) ENTPD2CA1CA2CA12CA9
SCHEMBL3098005 0.76 CA12 (0.36) ENTPD2CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100247463-A1 N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE YU RUEY J 2010-09-30 US claimed
EP-2019834-B1 ECTONUCLEOTIDASE INHIBITORS UNIV BONN (DE) 2014-07-09 EP disclosed
US-20100204182-A1 ECTONUCLEOTIDASE INHIBITORS RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) 2010-08-12 US disclosed
EP-2019834-A1 ECTONUCLEOTIDASE INHIBITORS Rheinische Friedrich-Wilhelms-Universität Bonn (DE) 2009-02-04 EP disclosed
WO-2007135195-A1 ECTONUCLEOTIDASE INHIBITORS Rheinische Friedrich-Wilhelms-Universität Bonn (DE) 2007-11-29 WO disclosed
EP-1860113-A1 Ectonucleotidase inhibitors Rheinische Friedrich-Wilhelms-Universität Bonn (DE) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204182-A1 ECTONUCLEOTIDASE INHIBITORS NT5E, NT5C2, ENTPD1 CYP1A2 1340/4885ENTPD2 10/4885CA1 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.